You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Displaying Guidelines

361 Items

Enhancing the Delivery of Take-Home Cancer Drugs in Ontario

Document Status: Current

Mar 2019

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Document Status: Archived
ID: 1-6

Sep 2011

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Document Status: Current
ID: PET 2023-1

Nov 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Document Status: Current
ID: PET 2024-1

Updated

Mar 2025

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2018

Document Status: Current
ID: PET 2018-2

Jul 2019

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2022

Document Status: Current
ID: PET 2022-2

Jun 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2023

Document Status: Current
Version: PET 2023-2

Jun 2024

Exercise for People with Cancer

Document Status: Current
ID: 19-5
Version: 2

Jul 2024

Expert Recommendation Report on Clinical Nurse Specialist and Nurse Practitioner Roles in the Delivery of Adult Cancer Services in Ontario

Document Status: Current
Version: 1

Jan 2018

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Document Status: Current
ID: SCT 5

Aug 2013

First-Line Therapy, Autologous Stem Cell Transplantation, and Post-Transplant Maintenance in the Management of Patients Newly Diagnosed with Mantle Cell Lymphoma

Document Status: In-Review
ID: RR SCT-9
Version: N/A

Jun 2020

First-line treatment of advanced-stage Hodgkin lymphoma

Document Status: Current
ID: ES 6-25

Oct 2024